-
1
-
-
0036733723
-
Increased prevalence of scleroderma in southwestern Ontario: A cluster analysis
-
Thompson AE, Pope JE. Increased prevalence of scleroderma in southwestern Ontario: A cluster analysis. J Rheumatol 2002;29:1867-73
-
(2002)
J Rheumatol
, vol.29
, pp. 1867-1873
-
-
Thompson, A.E.1
Pope, J.E.2
-
2
-
-
33847621190
-
Outcome measurements in scleroderma: Results from a Delphi exercise
-
Gazi H, Pope JE, Clements P, et al. Outcome measurements in scleroderma: Results from a Delphi exercise. J Rheumatol 2007;34:501-9
-
(2007)
J Rheumatol
, vol.34
, pp. 501-509
-
-
Gazi, H.1
Pope, J.E.2
Clements, P.3
-
3
-
-
82555191287
-
Risk factors associated with pulmonary arterial hypertension in patients with systemic sclerosis and implications for screening
-
Denton CP, Hachulla E. Risk factors associated with pulmonary arterial hypertension in patients with systemic sclerosis and implications for screening. Eur Respir Rev 2011;20(122):270-64
-
(2011)
Eur Respir Rev
, vol.20
, Issue.122
, pp. 270-264
-
-
Denton, C.P.1
Hachulla, E.2
-
4
-
-
34347266509
-
Changes in causes of death in systemic sclerosis 1972-2002
-
Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann rheum Dis 2007;66(7):940-4
-
(2007)
Ann Rheum Dis
, vol.66
, Issue.7
, pp. 940-944
-
-
Steen, V.D.1
Medsger, T.A.2
-
5
-
-
19944427793
-
Mortality in systemic sclerosis: An international meta-analysis of individual patient data
-
Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, et al. Mortality in systemic sclerosis: An international meta-analysis of individual patient data. Am J Med 2005;118(1):2-10
-
(2005)
Am J Med
, vol.118
, Issue.1
, pp. 2-10
-
-
Ioannidis, J.P.1
Vlachoyiannopoulos, P.G.2
Haidich, A.B.3
-
6
-
-
0038799768
-
Pulmonary hypertension in systemic sclerosis
-
vii
-
Denton CP, Black CM. Pulmonary hypertension in systemic sclerosis. Rheum Dis Clin North Am 2003;29(2):335-49; vii
-
(2003)
Rheum Dis Clin North Am
, vol.29
, Issue.2
, pp. 335-349
-
-
Denton, C.P.1
Black, C.M.2
-
7
-
-
29144536869
-
Early detection of pulmonary arterial hypertension in systemic sclerosis a French nationwide prospective multicenter study
-
Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: A French nationwide prospective multicenter study. Arthritis Rheum 2005;52(12):3792-800
-
(2005)
Arthritis Rheum
, vol.52
, Issue.12
, pp. 3792-3800
-
-
Hachulla, E.1
Gressin, V.2
Guillevin, L.3
-
8
-
-
22244434954
-
The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study)
-
Wigley FM, Lima JA, Mayes M, et al. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum 2005;52(7):2125-32
-
(2005)
Arthritis Rheum
, vol.52
, Issue.7
, pp. 2125-2132
-
-
Wigley, F.M.1
Lima, J.A.2
Mayes, M.3
-
9
-
-
2942541475
-
Cellular and molecular pathobiology of pulmonary arterial hypertension
-
Suppl I
-
Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(12 Suppl S):13S-24S
-
(2004)
J Am Coll Cardiol
, vol.43
, Issue.12
-
-
Humbert, M.1
Morrell, N.W.2
Archer, S.L.3
-
10
-
-
84866539030
-
Endothelial dysfunction in rheumatic autoimmune diseases
-
Murdaca G, Colombo BM, Cagnati P, et al. Endothelial dysfunction in rheumatic autoimmune diseases. Atherosclerosis 2012;224(2):309-17
-
(2012)
Atherosclerosis
, vol.224
, Issue.2
, pp. 309-317
-
-
Murdaca, G.1
Colombo, B.M.2
Cagnati, P.3
-
11
-
-
84878959825
-
Free radicals and endothelial dysfunction: Potential positive effects of TNF-alpha inhibitors
-
Murdaca G, Spanò F, Cagnati P, Puppo F. Free radicals and endothelial dysfunction: Potential positive effects of TNF-alpha inhibitors. Redox Rep 2013;18(3):95-9
-
(2013)
Redox Rep
, vol.18
, Issue.3
, pp. 95-99
-
-
Murdaca, G.1
Spanò, F.2
Cagnati, P.3
Puppo, F.4
-
12
-
-
0348110529
-
Endothelial function, inflammation, and prognosis in cardiovascular disease
-
Gonzalez MA, Selwyn AP. Endothelial function, inflammation, and prognosis in cardiovascular disease. Am J Med 2003;115(Suppl 8A):99S-106S
-
(2003)
Am J Med
, vol.115
, Issue.SUPPL.
-
-
Gonzalez, M.A.1
Selwyn, A.P.2
-
14
-
-
50949084102
-
Serum vascular endothelial growth factor in allergic rhinitis and systemic lupus erythematosus
-
Ciprandi G, Murdaca G, Colombo BM, et al. Serum vascular endothelial growth factor in allergic rhinitis and systemic lupus erythematosus. Hum Immunol 2008;69(8):510-12
-
(2008)
Hum Immunol
, vol.69
, Issue.8
, pp. 510-512
-
-
Ciprandi, G.1
Murdaca, G.2
Colombo, B.M.3
-
15
-
-
45149117511
-
Serum vascular endothelial growth factor and sublingual immunotherapy
-
Ciprandi G, Colombo BM, Murdaca G, De Amici M. Serum vascular endothelial growth factor and sublingual immunotherapy. Allergy 2008;63(7):945-6
-
(2008)
Allergy
, vol.63
, Issue.7
, pp. 945-946
-
-
Ciprandi, G.1
Colombo, B.M.2
Murdaca, G.3
De Amici, M.4
-
16
-
-
0032777126
-
Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cellspecific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth
-
Cool CD, Stewart JS, Werahera P, et al. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cellspecific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol 1999;155:411-19
-
(1999)
Am J Pathol
, vol.155
, pp. 411-419
-
-
Cool, C.D.1
Stewart, J.S.2
Werahera, P.3
-
17
-
-
84866618858
-
Immune and inflammatory mechanisms in pulmonary arterial hypertension
-
El Chami H, Hassoun PM. Immune and inflammatory mechanisms in pulmonary arterial hypertension. Prog Cardiovasc Dis 2012;55(2):218-28
-
(2012)
Prog Cardiovasc Dis
, vol.55
, Issue.2
, pp. 218-228
-
-
El Chami, H.1
Hassoun, P.M.2
-
18
-
-
0029062419
-
Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension
-
Humbert M, Monti G, Brenot F, et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995;151:1628-31
-
(1995)
Am J Respir Crit Care Med
, vol.151
, pp. 1628-1631
-
-
Humbert, M.1
Monti, G.2
Brenot, F.3
-
19
-
-
7044224579
-
Infliximab improves endothelial dysfunction in systemic vasculitis: A model of vascular inflammation
-
Booth AD, Jayne DR, Kharbanda RK, et al. Infliximab improves endothelial dysfunction in systemic vasculitis: A model of vascular inflammation. Circulation 2004;109(14):1718-23
-
(2004)
Circulation
, vol.109
, Issue.14
, pp. 1718-1723
-
-
Booth, A.D.1
Jayne, D.R.2
Kharbanda, R.K.3
-
21
-
-
80052459025
-
Pyruvate dehydrogenase inhibition by the inflammatory cytokine TNF-alpha contributes to the pathogenesis of pulmonary arterial hypertension
-
Sutendra G, Dromparis P, Bonnet S, et al. Pyruvate dehydrogenase inhibition by the inflammatory cytokine TNF-alpha contributes to the pathogenesis of pulmonary arterial hypertension. J Mol Med (Berl) 2011;89(8):771-83
-
(2011)
J Mol Med (Berl
, vol.89
, Issue.8
, pp. 771-783
-
-
Sutendra, G.1
Dromparis, P.2
Bonnet, S.3
-
22
-
-
84873721826
-
Interleukin-17a+ cell counts are increased in systemic sclerosis skin and their number is inversely correlated with the extent of skin involvement
-
Truchetet ME, Brembilla NC, Montanari E, et al. Interleukin-17A+ cell counts are increased in systemic sclerosis skin and their number is inversely correlated with the extent of skin involvement. Arthritis Rheum 2013;65(5):1347-56
-
(2013)
Arthritis Rheum
, vol.65
, Issue.5
, pp. 1347-1356
-
-
Truchetet, M.E.1
Brembilla, N.C.2
Montanari, E.3
-
23
-
-
81955160918
-
The role of th17 lymphocytes in the autoimmune and chronic inflammatory diseases
-
Murdaca G, Colombo BM, Puppo F. The role of Th17 lymphocytes in the autoimmune and chronic inflammatory diseases. Intern Emerg Med 2011;6(6):487-95
-
(2011)
Intern Emerg Med
, vol.6
, Issue.6
, pp. 487-495
-
-
Murdaca, G.1
Colombo, B.M.2
Puppo, F.3
-
24
-
-
61349192714
-
Traditional and non traditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: Role of vascular endothelial growth factor (VEGATS Study)
-
Colombo BM, Cacciapaglia F, Puntoni M, et al. Traditional and non traditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: Role of vascular endothelial growth factor (VEGATS Study). Autoimmun Rev 2009;8(4):309-15
-
(2009)
Autoimmun Rev
, vol.8
, Issue.4
, pp. 309-315
-
-
Colombo, B.M.1
Cacciapaglia, F.2
Puntoni, M.3
-
25
-
-
34948901886
-
Intima-media thickness: A marker of accelerated atherosclerosis in women with systemic lupus erythematosus
-
Colombo BM, Murdaca G, Caiti M, et al. Intima-media thickness: A marker of accelerated atherosclerosis in women with systemic lupus erythematosus. Ann NY Acad Sci 2007;1108:121-6
-
(2007)
Ann NY Acad Sci
, vol.1108
, pp. 121-126
-
-
Colombo, B.M.1
Murdaca, G.2
Caiti, M.3
-
26
-
-
0037331116
-
Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis
-
Kawut SM, Taichman DB, Archer-Chicko CL, et al. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003;123(2):344-50
-
(2003)
Chest
, vol.123
, Issue.2
, pp. 344-350
-
-
Kawut, S.M.1
Taichman, D.B.2
Archer-Chicko, C.L.3
-
27
-
-
77954758530
-
Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era
-
Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010;122:156-63
-
(2010)
Circulation
, Issue.122
, pp. 156-163
-
-
Humbert, M.1
Sitbon, O.2
Chaouat, A.3
-
28
-
-
77951961897
-
Survival in pulmonary arterial hypertension: A reappraisal of the NIH risk stratification equation
-
Thenappan T, Shah SJ, Rich S, et al. Survival in pulmonary arterial hypertension: A reappraisal of the NIH risk stratification equation. Eur Respir J 2010;35:1079-87
-
(2010)
Eur Respir J
, Issue.35
, pp. 1079-1087
-
-
Thenappan, T.1
Shah, S.J.2
Rich, S.3
-
29
-
-
77957286169
-
Causes and risk factors for death in systemic sclerosis: A study from the EULAR Scleroderma Trials and Research (EUSTAR) database
-
Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: A study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010;69:1809-15
-
(2010)
Ann Rheum Dis
, vol.69
, pp. 1809-1815
-
-
Tyndall, A.J.1
Bannert, B.2
Vonk, M.3
-
30
-
-
77955953602
-
Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension
-
Humbert M, Sitbon O, Yai?ci A, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010;36:549-55
-
(2010)
Eur Respir J
, Issue.36
, pp. 549-555
-
-
Humbert, M.1
Sitbon, O.2
Yaici, A.3
-
31
-
-
58449122578
-
Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era
-
Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009;179:151-7
-
(2009)
Am J Respir Crit Care Med
, vol.179
, pp. 151-157
-
-
Condliffe, R.1
Kiely, D.G.2
Peacock, A.J.3
-
32
-
-
74549213864
-
Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension
-
Dimopoulos K, Inuzuka R, Goletto S, et al. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation 2010;121:20-5
-
(2010)
Circulation
, Issue.121
, pp. 20-25
-
-
Dimopoulos, K.1
Inuzuka, R.2
Goletto, S.3
-
33
-
-
0038441800
-
Bosentan for the treatment of pulmonary arterial hypertension
-
Kenyon KW, Nappi JM. Bosentan for the treatment of pulmonary arterial hypertension. Ann Pharmacother 2003;37(7-8):1055-62
-
(2003)
Ann Pharmacother
, vol.37
, Issue.7-8
, pp. 1055-1062
-
-
Kenyon, K.W.1
Nappi, J.M.2
-
34
-
-
66149100618
-
EUSTAR Co-Authors EULAR recommendations for the treatment of systemic sclerosis: A report from the EULAR Scleroderma Trials and Research group (EUSTAR)
-
Kowal-Bielecka O, Landewé R, Avouac J, et al. EUSTAR Co-Authors. EULAR recommendations for the treatment of systemic sclerosis: A report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009;68(5):620-8
-
(2009)
Ann Rheum Dis
, vol.68
, Issue.5
, pp. 620-628
-
-
Kowal-Bielecka, O.1
Landewé, R.2
Avouac, J.3
-
35
-
-
0037149718
-
Bosentan therapy for pulmonary arterial hypertension
-
Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346(12):896-903
-
(2002)
N Engl J Med
, vol.346
, Issue.12
, pp. 896-903
-
-
Rubin, L.J.1
Badesch, D.B.2
Barst, R.J.3
-
36
-
-
0020410785
-
Psychophysical bases of perceived exertion
-
Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982;14(5):377-81
-
(1982)
Med Sci Sports Exerc
, vol.14
, Issue.5
, pp. 377-381
-
-
Borg, G.A.1
-
37
-
-
4544383466
-
Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2
-
Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004;24(3):353-9
-
(2004)
Eur Respir J
, vol.24
, Issue.3
, pp. 353-359
-
-
Humbert, M.1
Barst, R.J.2
Robbins, I.M.3
-
38
-
-
20044372707
-
Effects of the endothelin receptor antagonist bosentan on hemodynamics, symptoms and functional capacity in Japanese patients with severe pulmonary hypertension
-
Sasayama S, Kunieda T, Tomoike H, et al. Effects of the endothelin receptor antagonist bosentan on hemodynamics, symptoms and functional capacity in Japanese patients with severe pulmonary hypertension. Circ J 2005;69(2):131-7
-
(2005)
Circ J
, vol.69
, Issue.2
, pp. 131-137
-
-
Sasayama, S.1
Kunieda, T.2
Tomoike, H.3
-
39
-
-
57649188679
-
N-terminal pro-brain natriuretic peptide in systemic sclerosis related pulmonary arterial hypertension under bosentan treatment
-
Dimitroulas T, Giannakoulas G, Karvounis H, et al. N-terminal pro-brain natriuretic peptide in systemic sclerosis related pulmonary arterial hypertension under bosentan treatment. Rheumatol Int 2009;29(3):347-8
-
(2009)
Rheumatol Int
, vol.29
, Issue.3
, pp. 347-348
-
-
Dimitroulas, T.1
Giannakoulas, G.2
Karvounis, H.3
-
40
-
-
33746206340
-
Bosentan therapy in patients with Eisenmenger syndrome: A multicenter, double-blind, randomized, placebocontrolled study
-
Galiè N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: A multicenter, double-blind, randomized, placebocontrolled study. Circulation 2006;114:48-54
-
(2006)
Circulation
, vol.114
, pp. 48-54
-
-
Galiè, N.1
Beghetti, M.2
Gatzoulis, M.A.3
-
41
-
-
58249107821
-
Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities
-
McGoon MD, Frost AE, Oudiz RJ, et al. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest 2009;135:122-9
-
(2009)
Chest
, vol.135
, pp. 122-129
-
-
McGoon, M.D.1
Frost, A.E.2
Oudiz, R.J.3
-
42
-
-
46449124591
-
Ambrisentan for the treatment of pulmonary arterial hypertension: Results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2
-
Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double- Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group
-
Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double- Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group. Ambrisentan for the treatment of pulmonary arterial hypertension: Results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117(23):3010-19
-
(2008)
Circulation
, vol.117
, Issue.23
, pp. 3010-3019
-
-
Galiè, N.1
Olschewski, H.2
Oudiz, R.J.3
-
43
-
-
70350708667
-
Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension
-
Oudiz RJ, Galiè N, Olschewski H, et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54(21):1971-81
-
(2009)
J Am Coll Cardiol
, vol.54
, Issue.21
, pp. 1971-1981
-
-
Oudiz, R.J.1
Galiè, N.2
Olschewski, H.3
-
44
-
-
84858279164
-
ARIES-3: Ambrisentan therapy in a diverse population of patients with pulmonary hypertension
-
Badesch DB, Feldman J, Keogh A, et al. ARIES-3: Ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Cardiovasc Ther 2012;30(2):93-9
-
(2012)
Cardiovasc Ther
, vol.30
, Issue.2
, pp. 93-99
-
-
Badesch, D.B.1
Feldman, J.2
Keogh, A.3
-
45
-
-
84886518672
-
Ambrisentan for the treatment of pulmonary arterial hypertension: Improving outcomes
-
Elshaboury SM, Anderson Jr. Ambrisentan for the treatment of pulmonary arterial hypertension: Improving outcomes. Patient Prefer Adherence 2013;7:401-9
-
(2013)
Patient Prefer Adherence
, Issue.7
, pp. 401-409
-
-
Elshaboury, S.M.1
Anderson, J.R.2
-
46
-
-
84867754027
-
Safety and efficacy evaluation of ambrisentan in pulmonary hypertension
-
Vizza CD, Fedele F, Pezzuto B, Rubin LJ. Safety and efficacy evaluation of ambrisentan in pulmonary hypertension. Expert Opin Drug Saf 2012;11(6):1003-11
-
(2012)
Expert Opin Drug Saf
, vol.11
, Issue.6
, pp. 1003-1011
-
-
Vizza, C.D.1
Fedele, F.2
Pezzuto, B.3
Rubin, L.J.4
-
47
-
-
84881617288
-
Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials)
-
Maron BA, Waxman AB, Opotowsky AR, et al. Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials). Am J Cardiol 2013;112(5):720-5
-
(2013)
Am J Cardiol
, vol.112
, Issue.5
, pp. 720-725
-
-
Maron, B.A.1
Waxman, A.B.2
Opotowsky, A.R.3
-
48
-
-
57349133022
-
Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist
-
Iglarz M, Binkert C, Morrison K, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 2008;327(3):736-45
-
(2008)
J Pharmacol Exp Ther
, vol.327
, Issue.3
, pp. 736-745
-
-
Iglarz, M.1
Binkert, C.2
Morrison, K.3
-
49
-
-
84867562420
-
Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells
-
Gatfield J, Mueller Grandjean C, Sasse T, et al. Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. PLoS One 2012;7(10):e47662
-
(2012)
PLoS One
, vol.7
, Issue.10
-
-
Gatfield, J.1
Mueller Grandjean, C.2
Sasse, T.3
-
50
-
-
84883108940
-
Macitentan and morbidity and mortality in pulmonary arterial hypertension
-
Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013;369(9):809-18
-
(2013)
N Engl J Med
, vol.369
, Issue.9
, pp. 809-818
-
-
Pulido, T.1
Adzerikho, I.2
Channick, R.N.3
-
51
-
-
10744230817
-
Sitaxsentan therapy for pulmonary arterial hypertension
-
Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169(4):441-7
-
(2004)
Am J Respir Crit Care Med
, vol.169
, Issue.4
, pp. 441-447
-
-
Barst, R.J.1
Langleben, D.2
Frost, A.3
-
52
-
-
70349091119
-
Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension
-
Lavelle A, Sugrue R, Lawler G, et al. Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension. Eur Respir J 2009;34(3):770-1
-
(2009)
Eur Respir J
, vol.34
, Issue.3
, pp. 770-771
-
-
Lavelle, A.1
Sugrue, R.2
Lawler, G.3
-
53
-
-
33847410021
-
The nitric oxide/cGMP signaling pathway in pulmonary hypertension
-
Klinger Jr. The nitric oxide/cGMP signaling pathway in pulmonary hypertension. Clin Chest Med 2007;28(1):143-67
-
(2007)
Clin Chest Med
, vol.28
, Issue.1
, pp. 143-167
-
-
Klinger, J.R.1
-
54
-
-
26444534291
-
Sildenafil citrate therapy for pulmonary arterial hypertension
-
Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353(20):2148-57
-
(2005)
N Engl J Med
, vol.353
, Issue.20
, pp. 2148-2157
-
-
Galiè, N.1
Ghofrani, H.A.2
Torbicki, A.3
-
55
-
-
80052088060
-
Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: The super-2 study
-
Rubin LJ, Badesch DB, Fleming TR, et al. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: The SUPER-2 study. Chest 2011;140(5):1274-83
-
(2011)
Chest
, vol.140
, Issue.5
, pp. 1274-1283
-
-
Rubin, L.J.1
Badesch, D.B.2
Fleming, T.R.3
-
56
-
-
67649523052
-
Tadalafil therapy for pulmonary arterial hypertension
-
Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009;119(22):2894-903
-
(2009)
Circulation
, vol.119
, Issue.22
, pp. 2894-2903
-
-
Galiè, N.1
Brundage, B.H.2
Ghofrani, H.A.3
-
57
-
-
84865128907
-
Tadalafil for the treatment of pulmonary arterial hypertension: A double-blind 52- week uncontrolled extension study
-
Oudiz RJ, Brundage BH, Galiè N, et al. Tadalafil for the treatment of pulmonary arterial hypertension: A double-blind 52- week uncontrolled extension study. J Am Coll Cardiol 2012;60(8):768-74
-
(2012)
J Am Coll Cardiol
, vol.60
, Issue.8
, pp. 768-774
-
-
Oudiz, R.J.1
Brundage, B.H.2
Galiè, N.3
-
58
-
-
84883816682
-
Safety tolerability and efficacy of overnight switching from sildenafil to tadalafil in patients with pulmonary arterial hypertension
-
Shapiro S, Traiger G, Hill W, et al. Safety, tolerability, and efficacy of overnight switching from sildenafil to tadalafil in patients with pulmonary arterial hypertension. Cardiovasc Ther 2013;31(5):274-9
-
(2013)
Cardiovasc Ther
, vol.31
, Issue.5
, pp. 274-279
-
-
Shapiro, S.1
Traiger, G.2
Hill, W.3
-
59
-
-
37749007190
-
Oral tadalafil in pulmonary artery hypertension: A prospective study
-
Aggarwal P, Patial RK, Negi PC, Marwaha R. Oral tadalafil in pulmonary artery hypertension: A prospective study. Indian Heart J 2007;59(4):329-35
-
(2007)
Indian Heart J
, vol.59
, Issue.4
, pp. 329-335
-
-
Aggarwal, P.1
Patial, R.K.2
Negi, P.C.3
Marwaha, R.4
-
60
-
-
84863980719
-
Initial experience with tadalafil in pediatric pulmonary arterial hypertension
-
Takatsuki S, Calderbank M, Ivy DD. Initial experience with tadalafil in pediatric pulmonary arterial hypertension. Pediatr Cardiol 2012;33(5):683-8
-
(2012)
Pediatr Cardiol
, vol.33
, Issue.5
, pp. 683-688
-
-
Takatsuki, S.1
Calderbank, M.2
Ivy, D.D.3
-
61
-
-
80054752045
-
Initial and programmed combination therapy with oral drugs for severe idiopathic pulmonary arterial hypertension
-
Maki H, Yao A, Inaba T, et al. Initial and programmed combination therapy with oral drugs for severe idiopathic pulmonary arterial hypertension. Int Heart J 2011;52(5):323-6
-
(2011)
Int Heart J
, vol.52
, Issue.5
, pp. 323-326
-
-
Maki, H.1
Yao, A.2
Inaba, T.3
-
62
-
-
84862776722
-
Ambrisentan and tadalafil synergistically relax endothelin-induced contraction of rat pulmonary arteries
-
Liang F, Yang S, Yao L, et al. Ambrisentan and tadalafil synergistically relax endothelin-induced contraction of rat pulmonary arteries. Hypertension 2012;59(3):705-11
-
(2012)
Hypertension
, vol.59
, Issue.3
, pp. 705-711
-
-
Liang, F.1
Yang, S.2
Yao, L.3
-
63
-
-
79960961614
-
Pulmonary arterial hypertension: Changing approaches to management
-
Sidorenko BA, Preobrazhenskii DV, Batyraliev TA, Belenkov IuN. Pulmonary arterial hypertension: Changing approaches to management. Kardiologiia 2011;51(1):100-8
-
(2011)
Kardiologiia
, vol.51
, Issue.1
, pp. 100-108
-
-
Sidorenko, B.A.1
Preobrazhenskii, D.V.2
Batyraliev, T.A.3
Belenkov Iu, N.4
-
64
-
-
0036682273
-
Inhaled iloprost for severe pulmonary hypertension
-
Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347(5):322-9
-
(2002)
N Engl J Med
, vol.347
, Issue.5
, pp. 322-329
-
-
Olschewski, H.1
Simonneau, G.2
Galiè, N.3
-
65
-
-
21544449424
-
Clinical efficacy and survival with firstline inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension
-
Opitz CF, Wensel R, Winkler J, et al. Clinical efficacy and survival with firstline inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J 2005;26(18):1895-902
-
(2005)
Eur Heart J
, vol.26
, Issue.18
, pp. 1895-1902
-
-
Opitz, C.F.1
Wensel, R.2
Winkler, J.3
-
66
-
-
84882259677
-
Inhaled iloprost plus oral sildenafil in patients with severe pulmonary arterial hypertension delays the need for lung transplantation
-
Lopez-Meseguer M, Berastegui C, Monforte V, et al. Inhaled iloprost plus oral sildenafil in patients with severe pulmonary arterial hypertension delays the need for lung transplantation. Transplant Proc 2013;45(6):2347-50
-
(2013)
Transplant Proc
, vol.45
, Issue.6
, pp. 2347-2350
-
-
Lopez-Meseguer, M.1
Berastegui, C.2
Monforte, V.3
-
67
-
-
0038037766
-
Beraprost therapy for pulmonary arterial hypertension
-
Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003;41(12):2119-25
-
(2003)
J Am Coll Cardiol
, vol.41
, Issue.12
, pp. 2119-2125
-
-
Barst, R.J.1
McGoon, M.2
McLaughlin, V.3
-
68
-
-
0025356811
-
Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol) Results of a randomized trial
-
Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990;112(7):485-91
-
(1990)
Ann Intern Med
, vol.112
, Issue.7
, pp. 485-491
-
-
Rubin, L.J.1
Mendoza, J.2
Hood, M.3
-
69
-
-
0028597038
-
Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin
-
Barst RJ, Rubin LJ, McGoon MD, et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994;121(6):409-15
-
(1994)
Ann Intern Med
, vol.121
, Issue.6
, pp. 409-415
-
-
Barst, R.J.1
Rubin, L.J.2
McGoon, M.D.3
-
70
-
-
0030031888
-
A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
-
Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334(5):296-301
-
(1996)
N Engl J Med
, vol.334
, Issue.5
, pp. 296-301
-
-
Barst, R.J.1
Rubin, L.J.2
Long, W.A.3
-
71
-
-
0037086133
-
Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: A double-blind, randomized, placebo-controlled trial
-
Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: A double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165(6):800-4
-
(2002)
Am J Respir Crit Care Med
, vol.165
, Issue.6
, pp. 800-804
-
-
Simonneau, G.1
Barst, R.J.2
Galie, N.3
-
72
-
-
77952301237
-
Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: A randomized controlled clinical trial
-
McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: A randomized controlled clinical trial. J Am Coll Cardiol 2010;55(18):1915-22
-
(2010)
J Am Coll Cardiol
, vol.18
, Issue.55
, pp. 1915-1922
-
-
McLaughlin, V.V.1
Benza, R.L.2
Rubin, L.J.3
-
73
-
-
12244251412
-
Efficacy and safety of treprostinil: An epoprostenol analog for primary pulmonary hypertension
-
McLaughlin VV, Gaine SP, Barst RJ, et al. Efficacy and safety of treprostinil: An epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol 2003;41(2):293-9
-
(2003)
J Cardiovasc Pharmacol
, vol.41
, Issue.2
, pp. 293-299
-
-
McLaughlin, V.V.1
Gaine, S.P.2
Barst, R.J.3
-
74
-
-
84873566367
-
Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: A randomized controlled trial
-
Jing ZC, Parikh K, Pulido T, et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: A randomized, controlled trial. Circulation 2013;127(5):624-33
-
(2013)
Circulation
, vol.127
, Issue.5
, pp. 624-633
-
-
Jing, Z.C.1
Parikh, K.2
Pulido, T.3
-
75
-
-
84874948946
-
Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: Results of the randomized impres study
-
Hoeper MM, Barst RJ, Bourge RC, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: Results of the randomized IMPRES study. Circulation 2013;127(10):1128-38
-
(2013)
Circulation
, vol.127
, Issue.10
, pp. 1128-1138
-
-
Hoeper, M.M.1
Barst, R.J.2
Bourge, R.C.3
-
76
-
-
84555190230
-
Update upon efficacy and safety of tnf-alpha inhibitors
-
Murdaca G, Colombo BM, Cagnati P, et al. Update upon efficacy and safety of TNF-alpha inhibitors. Expert Opin Drug Saf 2012;11(1):1-5
-
(2012)
Expert Opin Drug Saf
, vol.11
, Issue.1
, pp. 1-5
-
-
Murdaca, G.1
Colombo, B.M.2
Cagnati, P.3
-
77
-
-
80855130786
-
Emerging biological drugs: A new therapeutic approach for systemic lupus erythematosus an update upon efficacy and adverse events
-
Murdaca G, Colombo BM, Puppo F. Emerging biological drugs: A new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events. Autoimmun Rev 2011;11(1):56-60
-
(2011)
Autoimmun Rev
, vol.11
, Issue.1
, pp. 56-60
-
-
Murdaca, G.1
Colombo, B.M.2
Puppo, F.3
-
78
-
-
80052748895
-
Adalimumab for the treatment of immune-mediated diseases: An update on old and recent indications
-
Murdaca G, Colombo BM, Puppo F. Adalimumab for the treatment of immune-mediated diseases: An update on old and recent indications. Drugs Today (Barc) 2011;47(4):277-88
-
(2011)
Drugs Today (Barc
, vol.47
, Issue.4
, pp. 277-288
-
-
Murdaca, G.1
Colombo, B.M.2
Puppo, F.3
-
79
-
-
70350551948
-
Anti-TNF-alpha inhibitors: A new therapeutic approach for inflammatory immune-mediated diseases: An update upon efficacy and adverse events
-
Murdaca G, Colombo BM, Puppo F. Anti-TNF-alpha inhibitors: A new therapeutic approach for inflammatory immune-mediated diseases: An update upon efficacy and adverse events. Int J Immunopathol Pharmacol 2009;22(3):557-65
-
(2009)
Int J Immunopathol Pharmacol
, vol.22
, Issue.3
, pp. 557-565
-
-
Murdaca, G.1
Colombo, B.M.2
Puppo, F.3
-
80
-
-
79952116693
-
Anti-tumor necrosis factor-alpha treatment with infliximab for disseminated granuloma annulare
-
Murdaca G, Colombo BM, Barabino G, et al. Anti-tumor necrosis factor-alpha treatment with infliximab for disseminated granuloma annulare. Am J Clin Dermatol 2010;11(6):437-9
-
(2010)
Am J Clin Dermatol
, vol.11
, Issue.6
, pp. 437-439
-
-
Murdaca, G.1
Colombo, B.M.2
Barabino, G.3
-
81
-
-
26244456344
-
Emerging biologic drugs for the treatment of rheumatoid arthritis
-
Puppo F, Murdaca G, Ghio M, Indiveri F. Emerging biologic drugs for the treatment of rheumatoid arthritis. Autoimmun Rev 2005;4(8):537-41
-
(2005)
Autoimmun Rev
, vol.4
, Issue.8
, pp. 537-541
-
-
Puppo, F.1
Murdaca, G.2
Ghio, M.3
Indiveri, F.4
-
82
-
-
84886626779
-
Use of leflunomide plus tnf-alpha inhibitors in rheumatoid arthritis
-
Murdaca G, Spanò F, Puppo F. Use of leflunomide plus TNF-alpha inhibitors in rheumatoid arthritis. Expert Opin Drug Saf 2013;12(6):801-4
-
(2013)
Expert Opin Drug Saf
, vol.12
, Issue.6
, pp. 801-804
-
-
Murdaca, G.1
Spanò, F.2
Puppo, F.3
-
83
-
-
84874178736
-
Selective tnf-alpha inhibitor-induced injection site reactions
-
Murdaca G, Spanò F, Puppo F. Selective TNF-alpha inhibitor-induced injection site reactions. Expert Opin Drug Saf 2013;12(2):187-93
-
(2013)
Expert Opin Drug Saf
, vol.12
, Issue.2
, pp. 187-193
-
-
Murdaca, G.1
Spanò, F.2
Puppo, F.3
-
84
-
-
84862234099
-
Determination of lymphotoxin-alpha levels in patients with psoriatic arthritis undergoing etanercept treatment
-
Murdaca G, Colombo BM, Contini P, Puppo F. Determination of lymphotoxin-alpha levels in patients with psoriatic arthritis undergoing etanercept treatment. J Interferon Cytokine Res 2012;32(6):277-9
-
(2012)
J Interferon Cytokine Res
, vol.32
, Issue.6
, pp. 277-279
-
-
Murdaca, G.1
Colombo, B.M.2
Contini, P.3
Puppo, F.4
-
85
-
-
84867368217
-
Long-term safety and effectiveness of tumour necrosis factor inhibitors in systemic sclerosis patients with inflammatory arthritis
-
Omair MA, Phumethum V, Johnson SR. Long-term safety and effectiveness of tumour necrosis factor inhibitors in systemic sclerosis patients with inflammatory arthritis. Clin Exp Rheumatol 2012;30(2 Suppl 71):S55-9
-
(2012)
Clin Exp Rheumatol
, vol.30
, Issue.2 SUPPL.
-
-
Omair, M.A.1
Phumethum, V.2
Johnson, S.R.3
-
86
-
-
21744459538
-
Chronic tumor necrosis factor-alpha inhibition enhances NO modulation of vascular function in estrogen-deficient rats
-
Arenas IA, Armstrong SJ, Xu Y, Davidge ST. Chronic tumor necrosis factor-alpha inhibition enhances NO modulation of vascular function in estrogen-deficient rats. Hypertension 2005;46(1):76-81
-
(2005)
Hypertension
, vol.46
, Issue.1
, pp. 76-81
-
-
Arenas, I.A.1
Armstrong, S.J.2
Xu, Y.3
Davidge, S.T.4
-
87
-
-
84864080031
-
The effect of tumor necrosis factora antagonists on arterial stiffness in rheumatoid arthritis: A literature review
-
Dulai R, Perry M, Twycross-Lewis R, et al. The effect of tumor necrosis factora antagonists on arterial stiffness in rheumatoid arthritis: A literature review. Semin Arthritis Rheum 2012;42(1):1-8
-
(2012)
Semin Arthritis Rheum
, vol.42
, Issue.1
, pp. 1-8
-
-
Dulai, R.1
Perry, M.2
Twycross-Lewis, R.3
-
88
-
-
75049085546
-
Vascular effects of biologic agents in RA and spondyloarthropathies
-
Szekanecz Z, Kerekes G, Soltész P. Vascular effects of biologic agents in RA and spondyloarthropathies. Nat Rev Rheumatol 2009;5(12):677-84
-
(2009)
Nat Rev Rheumatol
, vol.5
, Issue.12
, pp. 677-684
-
-
Szekanecz, Z.1
Kerekes, G.2
Soltész, P.3
-
89
-
-
84874089328
-
Effects of TNF-A inhibitors upon the mechanisms of action of VEGF
-
Murdaca G, Spanò F, Miglino M, Puppo F. Effects of TNF-a inhibitors upon the mechanisms of action of VEGF. Immunotherapy 2013;5(2):113-15
-
(2013)
Immunotherapy
, vol.5
, Issue.2
, pp. 113-115
-
-
Murdaca, G.1
Spanò, F.2
Miglino, M.3
Puppo, F.4
-
90
-
-
41349096428
-
Infliximab treatment in a patient with systemic sclerosis associated with lung fibrosis and pulmonary hypertension
-
Bargagli E, Galeazzi M, Bellisai F, et al. Infliximab treatment in a patient with systemic sclerosis associated with lung fibrosis and pulmonary hypertension. Respiration 2008;75:346-9
-
(2008)
Respiration
, vol.75
, pp. 346-349
-
-
Bargagli, E.1
Galeazzi, M.2
Bellisai, F.3
-
91
-
-
84871720484
-
Monocrotaline-induced pulmonary arterial hypertension is attenuated by tnf-alpha antagonists via the suppression of tnf-alpha expression and nf-kappab pathway in rats
-
Wang Q, Zuo XR, Wang YY, et al. Monocrotaline-induced pulmonary arterial hypertension is attenuated by TNF-alpha antagonists via the suppression of TNF-alpha expression and NF-kappaB pathway in rats. Vascul Pharmacol 2013;58(1-2):71-7
-
(2013)
Vascul Pharmacol
, vol.58
, Issue.1-2
, pp. 71-77
-
-
Wang, Q.1
Zuo, X.R.2
Wang, Y.Y.3
-
92
-
-
19644364586
-
The benefit/risk profile of TNFblocking agents: Findings of a consensus panel
-
Hochberg MC, Lebwohl MG, Plevy SE, et al. The benefit/risk profile of TNFblocking agents: Findings of a consensus panel. Semin Arthritis Rheum 2005;34:819-36
-
(2005)
Semin Arthritis Rheum
, vol.34
, pp. 819-836
-
-
Hochberg, M.C.1
Lebwohl, M.G.2
Plevy, S.E.3
-
93
-
-
79957927386
-
Anti-TNF therapy: Safety aspects of taking the risk
-
Rosenblum H, Amital H. Anti-TNF therapy: Safety aspects of taking the risk. Autoimmun Rev 2011;10:563-8
-
(2011)
Autoimmun Rev
, Issue.10
, pp. 563-568
-
-
Rosenblum, H.1
Amital, H.2
-
94
-
-
33846144397
-
Immunogenicity, efficacy and adverse events of adalimumab in RA patients
-
Bender NK, Heilig CE, Dr€oll B, et al. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int 2007;27:269-74
-
(2007)
Rheumatol Int
, vol.27
, pp. 269-274
-
-
Bender, N.K.1
Heilig, C.E.2
Droll, B.3
|